Bloomberg Best features the best stories of the day from Bloomberg Radio, Bloomberg Television, and 120 countries around the world.

Historically Black colleges and universities are the focus of this young businessman's fashion clothing line. Crazy trick-shots have become the burgeoning toy enterprise of another hustle. And finally, one man has turned training for the thankless, grueling position of offensive lineman into a path toward personal physical fulfillment.

‘How’s That for a Lesson?’: Wall Street Reviews Rocky Six Months

Nearly All of Wall Street – and the Fed – Botched Calls for 2022

Aerojet CEO’s Board Candidates Backed by ISS in Proxy Fight

Payment Technology Company Paya to Explore Sale

Rogers, Shaw to Sell Mobile Unit to Quebecor for $2.2 Billion

Congo’s M23 Rebels Plan to Take Trading Hub Goma, UN Report Says

Biden Says He and China’s Xi to Talk ‘Soon,’ Weighing Tariffs

America’s Top 1% Lose $1.5 Trillion on Stocks Before Bear Market

Gold Billionaire to Moonlight as DJ at Sold-Out Cairo Club

Naomi Osaka Won't Play at Wimbledon, Citing Achilles Tendon

US Open Updates: Zalatoris Makes Move, -2 Through 4 Holes

Why Is the Cost of Rent Going Up? Ask the Fed

Extra Fees Are Adding Insult to Consumers’ Injury

Why Is It So Hard to Find a Decent Public Bathroom?

Adults Who Love Toys? The Toy Industry Loves Them, Too

ESPN’s NHL Deal Shows Broadcasters a New Way to Profit From Sports Rights

America’s Convention Center Kings Want You Wearing Lanyards Again

‘Banking While Black’ Is the Next Target for Civil Rights Lawyer

NYC Mayor Adams Allocates $6.7 Million Toward LGBTQ Social Services

A Quarter of All Abortion Clinics Would Close in US If Roe Is Overturned

ESG Funds Resist Worst of Downturn But Investors Are Spooked

Yellowstone Flooding Rebuild Could Take Years, Cost Billions

The Museum Seeking to Unlock a War-Hit Nation’s Mineral Wealth

Rikers Jail Replacement Plan Pits Chinatown Against New York City

Without Commuters, US Transit Agencies Are Running Out of Options

DeFi Platform MakerDAO Pauses Some Aave-Related Lending Activity

Memories of Bitcoin-Beating Returns Keep Hex Holders Hanging On

Musk Signals ‘Maybe More Down the Road’ for Dogecoin After Merch

New study data showed Pfizer Inc.’s experimental Covid-19 pill was highly effective at keeping patients out of the hospital, but less adept at erasing milder symptoms often associated with breakthrough infections.

Pfizer disclosed findings from two studies in a statement Tuesday. In one, its treatment, Paxlovid, failed to meet the primary goal of reducing self-reported symptoms in 673 adults at standard risk of developing Covid-19 complications. The drug showed a trend toward reducing hospitalizations in the group by 70%, however.